{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-25-000173","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.328657+00:00","generated_at":"2026-05-16T23:51:42.793080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pliant Therapeutics Q3 net loss narrows to $26.3M; BEACON-IPF close out near completion","bullets":["Net loss $26.3M vs $57.8M YoY; R&D expense fell to $17.9M from $47.8M.","Cash, equivalents and short-term investments $243.3M as of Sept 30, 2025.","Phase 1 trial of PLN-101095 completed enrollment; data expected Q4 2025.","BEACON-IPF close out activities to be completed in Q4 2025.","Voluntary prepayment of Oxford Finance LLC loan completed in October 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-25-000173","json":"https://secwatch.observer/filing/0001746473-25-000173.json","markdown":"https://secwatch.observer/filing/0001746473-25-000173.md","text":"https://secwatch.observer/filing/0001746473-25-000173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/0001746473-25-000173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/plrx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:51:42.793080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}